Top Markets
#1 Black Phoenix Black Phoenix +166.95%
#2 Islamic Coin Islamic Coin +158.16%
#3 Glidr Glidr +84.34%
#4 Acurast Acurast +46.33%
#5 Cryptopia Cryptopia +20.92%
#6 Test Test +19.84%
#7 Quantum Resistant Ledger Quantum Resistant Ledger +19.61%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.95%
#9 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +9.99%
#10 Useless Coin Useless Coin +8.99%
Coin of the day
Black Phoenix Black Phoenix
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Q BioMed Inc. Q BioMed Inc.

Q BioMed Inc.

QBIO
Rang in Aktien #41615
Q BioMed Inc. functions as a biomedical accelerator and developer, actively... Q BioMed Inc. functions as a biomedical accelerator and developer, actively licensing, acquiring, and supplying resources to firms within the life sciences and healthcare sectors. Its commercial portfolio includes Metastron (Strontium Chloride SR89), a radiopharmaceutical designed to alleviate pain associated with metastatic bone cancer. Additionally, Q BioMed is advancing a pipeline of therapeutic candidates, including Man-01, a pre-clinical compound aimed at primary open-angle glaucoma; QBM-001, intended for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, which targets liver cancer. The company also collaborates with Mannin Research Inc. on the development of treatments for conditions such as acute respiratory distress syndrome, glaucoma, and various kidney diseases. Incorporated in New York, New York, in 2013, the entity was initially named ISMO Tech Solutions, Inc. before adopting its current name, Q BioMed Inc., in July 2015.
Aktienkurs
$0.0001
Zuletzt synchronisiert: 2026-04-02
Marktkapitalisierung
$14.51K
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
9,900.00%
Land
US
Handel Q BioMed Inc. (QBIO)

Kategorie

Healthcare
P/B-Verhältnis für Q BioMed Inc. (QBIO)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Q BioMed Inc. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für Q BioMed Inc. von 2026 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR